Zevra Therapeutics, Inc. ZVRA Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Zevra Therapeutics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Zevra Therapeutics, Inc.'s operating cash flow?
- Zevra Therapeutics, Inc. (ZVRA) reported operating cash flow of $6.14M in Q1 2026.
- How has Zevra Therapeutics, Inc.'s operating cash flow changed year-over-year?
- Zevra Therapeutics, Inc.'s operating cash flow increased by 174.7% year-over-year, from -$8.22M to $6.14M.
- What is the long-term trend for Zevra Therapeutics, Inc.'s operating cash flow?
- Over 2 years (2022 to 2024), Zevra Therapeutics, Inc.'s operating cash flow has grown at a 92.9% compound annual growth rate (CAGR), from -$18.72M to -$69.67M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.